UNSPSC 51293602: Amedalin

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2OWK6X9N16. European Medicines Agency schedules Amedalin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05406MIG. Amedalin generally arises in the molecular formula C19H22N2O.

UNSPSC 51293602 Amedalin is a Commodity code for pharmaceutical products and related health interventions. State and local governments procure naloxone, drug deactivation systems, generic pharmaceuticals, and over-the-counter products under this code to support community health programs, emergency response capabilities, and ongoing healthcare delivery across county health departments, state health and human services agencies, and cooperative purchasing consortia. The issuing bodies include county health systems, state health departments, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions.

Recent activity centers in Florida and Texas, with multistate procurement through Minnesota's MMCAP cooperative. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; response deadline was July 26, 2023. The Texas Health and Human Services Commission posted Request for Information HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct relationships between the state pharmacy benefit program and manufacturers. The Minnesota Department of Administration, through MMCAP, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and over-the-counter products to be distributed across state and local government facilities in Minnesota and Oregon; proposals were due March 26, 2026, with contract effectiveness July 1, 2026. Vendors competing under this code must comply with cGMP certification, Drug Supply Chain Security Act requirements, FDA regulations, and maintain substantial insurance coverage including workers' compensation and commercial general liability of at least $5 million per occurrence. Cooperative purchasing vehicles and multistate frameworks dominate the landscape, with awarded vendors typically required to supply products through specified authorized wholesalers and meet performance metrics with penalties for late reporting or missed onboarding timelines.